Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA.
Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
Hum Vaccin Immunother. 2022 Nov 30;18(5):2045857. doi: 10.1080/21645515.2022.2045857. Epub 2022 Mar 3.
The U.S. Centers for Disease Control and Prevention (CDC) and other health agencies have recently recommended a booster dose of COVID-19 vaccines for specific vulnerable groups including adults 65 years and older. There is limited evidence whether vaccine effectiveness (VE) in older adults decreases over time, especially against severe COVID-19. We performed a rapid review of published studies available through 4 November 2021 that provide effectiveness data on messenger RNA (mRNA) vaccines approved/licensed in the United States and identified eight eligible studies which evaluated VE in older adults. There is evidence of a decline in VE against both severe acute respiratory syndrome coronavirus 2 infection and severe COVID-19 in older adults among studies which analyzed data up to July-October 2021. Our findings suggest that VE diminishes in older adults, which supports the current recommendation for a booster dose in this population.
美国疾病控制与预防中心（CDC）和其他卫生机构最近建议为包括 65 岁及以上成年人在内的特定弱势群体接种 COVID-19 疫苗加强针。关于老年人的疫苗有效性（VE）是否会随着时间的推移而降低，特别是针对严重 COVID-19 的情况，目前证据有限。我们对截至 2021 年 11 月 4 日已发表的研究进行了快速审查，这些研究提供了在美国获得批准/许可的信使 RNA（mRNA）疫苗的有效性数据，并确定了八项评估老年人 VE 的合格研究。有证据表明，在分析截至 2021 年 7 月至 10 月的数据的研究中，老年人中针对严重急性呼吸综合征冠状病毒 2 感染和严重 COVID-19 的 VE 下降。我们的研究结果表明，老年人的 VE 减弱，这支持了目前在该人群中推荐加强针的建议。
